Compugen (CGEN) - Total Liabilities
Based on the latest financial reports, Compugen (CGEN) has total liabilities worth ILA54.02 Million ILA (≈ $144.82K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Compugen to assess how effectively this company generates cash.
Compugen - Total Liabilities Trend (1999–2024)
This chart illustrates how Compugen's total liabilities have evolved over time, based on quarterly financial data. Check Compugen asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Compugen Competitors by Total Liabilities
The table below lists competitors of Compugen ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
China | CN¥510.98 Million |
|
Amcil Ltd
AU:AMH
|
Australia | AU$32.62 Million |
|
Daehan Steel
KO:084010
|
Korea | ₩311.32 Billion |
|
Berjaya Assets Bhd
KLSE:3239
|
Malaysia | RM1.19 Billion |
|
X-Legend Entertainment Co Ltd
TW:4994
|
Taiwan | NT$435.07 Million |
|
Saksoft Limited
NSE:SAKSOFT
|
India | Rs2.95 Billion |
|
Magnora ASA
OL:MGN
|
Norway | Nkr110.20 Million |
|
Security National Financial
NASDAQ:SNFCA
|
USA | $1.16 Trillion |
Liability Composition Analysis (1999–2024)
This chart breaks down Compugen's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CGEN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Compugen's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Compugen (1999–2024)
The table below shows the annual total liabilities of Compugen from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA60.08 Million ≈ $161.08K |
+7.72% |
| 2023-12-31 | ILA55.77 Million ≈ $149.53K |
+238.11% |
| 2022-12-31 | ILA16.50 Million ≈ $44.23K |
-35.23% |
| 2021-12-31 | ILA25.47 Million ≈ $68.28K |
+37.42% |
| 2020-12-31 | ILA18.53 Million ≈ $49.69K |
+20.02% |
| 2019-12-31 | ILA15.44 Million ≈ $41.40K |
-3.11% |
| 2018-12-31 | ILA15.94 Million ≈ $42.73K |
+68.66% |
| 2017-12-31 | ILA9.45 Million ≈ $25.33K |
+24.00% |
| 2016-12-31 | ILA7.62 Million ≈ $20.43K |
-19.02% |
| 2015-12-31 | ILA9.41 Million ≈ $25.23K |
+6.09% |
| 2014-12-31 | ILA8.87 Million ≈ $23.78K |
-64.27% |
| 2013-12-31 | ILA24.82 Million ≈ $66.55K |
+120.90% |
| 2012-12-31 | ILA11.24 Million ≈ $30.13K |
+18.28% |
| 2011-12-31 | ILA9.50 Million ≈ $25.47K |
+16.24% |
| 2010-12-31 | ILA8.17 Million ≈ $21.91K |
+193.25% |
| 2009-12-31 | ILA2.79 Million ≈ $7.47K |
-34.28% |
| 2008-12-31 | ILA4.24 Million ≈ $11.37K |
-3.20% |
| 2007-12-31 | ILA4.38 Million ≈ $11.75K |
-14.40% |
| 2006-12-31 | ILA5.12 Million ≈ $13.72K |
-12.63% |
| 2005-12-31 | ILA5.86 Million ≈ $15.71K |
+1.23% |
| 2004-12-31 | ILA5.79 Million ≈ $15.51K |
-25.02% |
| 2003-12-31 | ILA7.72 Million ≈ $20.69K |
-7.86% |
| 2002-12-31 | ILA8.38 Million ≈ $22.46K |
+15.90% |
| 2001-12-31 | ILA7.23 Million ≈ $19.38K |
+34.78% |
| 2000-12-31 | ILA5.36 Million ≈ $14.38K |
+96.34% |
| 1999-12-31 | ILA2.73 Million ≈ $7.32K |
-- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more